XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Operating activities    
Net income (loss) $ 79,203 $ (158,239)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization 4,243 2,728
Stock-based compensation expense 21,418 32,312
Impairment of out-license asset and remeasurement of CVR liability, net 6,772  
Loss on debt extinguishment 12,630  
Gain on Sale Transaction, net (Note 6) (176,646)  
Inventory write-downs, net 2,481 4,369
Other non-cash adjustments, net (505) 78
Changes in operating assets and liabilities:    
Trade receivables, net 93,024 (106,626)
Inventory (25,499) (34,941)
Prepaid manufacturing 5,582 4,108
Other prepaid, current and non-current assets (4,306) 10,702
Accounts payable (10,280) 24,545
Accrued rebates, fees and reserves (7,617) 60,602
TSA related operating assets and liabilities, net (Note 6) 2,396  
Accrued compensation (1,039) (8,810)
Accrued and other current and non-current liabilities (50,905) 7,225
Net cash used in operating activities (49,048) (161,947)
Investing activities    
Proceeds from maturities of investments in marketable securities 6,200 108,148
Proceeds from sale of investments in marketable securities 8,688 13,282
Cash and cash equivalents acquired from Surface Acquisition   6,997
Milestone based license fee payment to Junshi Biosciences (12,500)  
Purchases of investments in marketable securities   (19,507)
Other investing activities, net 652 517
Net cash provided by investing activities 230,863 109,437
Financing activities    
Proceeds from 2029 Term Loan, net of debt discount & issuance costs 36,979  
Proceeds from Revenue Purchase and Sale Agreement, net of issuance costs 36,486  
Proceeds from issuance of common stock upon exercise of stock options 291 170
Proceeds from purchase under the employee stock purchase plan 685 1,337
Taxes paid related to net share settlement (2,466) (3,261)
Repayment of 2027 Term Loans, premiums and exit fees (260,387)  
Other financing activities (248) (835)
Net cash (used in) provided by financing activities (187,205) 69,234
Net (decrease) increase in cash, cash equivalents and restricted cash (5,390) 16,724
Cash, cash equivalents and restricted cash at beginning of period 103,343 63,987
Cash, cash equivalents and restricted cash at end of period 97,953 80,711
Supplemental disclosures of non-cash activities    
Non-cash employee bonuses settled in common stock 4,408  
Financing issuance costs in accounts payable 859  
CIMERLI Sale    
Investing activities    
Cash received from Sale 187,823  
YUSIMRY Sale    
Investing activities    
Cash received from Sale 40,000  
At Market Offering [Member]    
Financing activities    
Proceeds from issuance of common stock, net of issuance costs $ 1,455 18,198
Public Offering    
Financing activities    
Proceeds from issuance of common stock, net of issuance costs   $ 53,625